SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0000905718-18-000191
Filing Date
2018-02-14
Accepted
2018-02-14 15:02:01
Documents
1
Group Members
ABINGWORTH BIOEQUITIES MASTER FUND LTDABINGWORTH BIOVENTURES VI, LP

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 cymabay_13gam1dec312017.htm SC 13G/A 82921
  Complete submission text file 0000905718-18-000191.txt   84664
Mailing Address 7999 GATEWAY BLVD SUITE 130 NEWARK CA 94560
Business Address 7999 GATEWAY BLVD SUITE 130 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Subject) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-87950 | Film No.: 18611379
SIC: 2834 Pharmaceutical Preparations

Mailing Address 38 JERMYN STREET LONDON X0 SW1Y 6DN
Business Address 38 JERMYN STREET LONDON X0 SW1Y 6DN 44 (0)20 7534 1500
Abingworth LLP (Filed by) CIK: 0001397144 (see all company filings)

IRS No.: 980518585 | State of Incorp.: X0 | Fiscal Year End: 0630
Type: SC 13G/A